<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">
      <span class="gem-c-organisation-logo__name">Medicines &amp; Healthcare products<br>Regulatory Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Decision
  </span>

  
  <h1 class="gem-c-title__text govuk-heading-xl">
    Conditions of Authorisation for Vaxzevria
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 5 January 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png">
</p>
<p>
  Â© Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/conditions-of-authorisation-for-covid-19-vaccine-astrazeneca--2
</p>


    </div>
  </div>

  <div class="main-content-container offset-empty-contents-list">
    <div class="gem-c-govspeak-html-publication">
  
<div data-module="govspeak" class="gem-c-govspeak govuk-govspeak ">
    
    
      <div class="govspeak">
<h2>Vaxzevria  (previously COVID-19 Vaccine AstraZeneca) Conditional Marketing Authorisation</h2>

<h3>
<span class="number">1. </span> Specific obligation to complete post-authorisation measures for the Conditional Marketing Authorisation</h3>

<p>This being a conditional marketing authorisation the Marketing Authorisation Holder (MAH) shall complete, within the stated timeframe, the following measures:</p>

<ul>
  <li>In order to confirm the consistency of the active substance and finished product manufacturing process, the MAH should provide additional validation and comparability data and introduce enhanced testing.
    <ul>
      <li>31 December 2021 with interim updates beginning July 2021</li>
    </ul>
  </li>
  <li>In order to ensure consistent product quality, the MAH should provide additional information on stability of the active substance and finished product (through the scheduled duration of 12 months) and review the finished product specifications following further manufacturing experience, where applicable.
    <ul>
      <li>30 June 2022 with interim updates beginning July 2021</li>
    </ul>
  </li>
  <li>In order to confirm the efficacy and safety of Vaxzevria, the MAH should submit the final Clinical Study Reports following all subjects for 1 year post second dose for the randomised, controlled, COV001, COV002, COV003 and COV005.
    <ul>
      <li>30 September 2022</li>
    </ul>
  </li>
  <li>In order to confirm the efficacy and safety of Vaxzevria, the MAH should provide the final analysis from the pooled pivotal studies.
    <ul>
      <li>30 September 2022</li>
    </ul>
  </li>
  <li>In order to confirm the efficacy and safety of Vaxzevria in the elderly and subjects with underlying disease, the MAH should submit the final clinical study report for study D8110C00001.
    <ul>
      <li>31 March 2024</li>
    </ul>
  </li>
</ul>

<h3>
<span class="number">2. </span> Obligation to conduct post-authorisation measures</h3>

<p>The Marketing Authorisation Holder (MAH) shall complete, within the stated timeframe, the below measures:</p>

<ul>
  <li>In order to elucidate the possible mechanisms of platelet activation after vaccination and to identify the possible triggers, the MAH should conduct and submit the final report for a non-clinical study to test in-vitro expression of the S protein of Vaxzevria.
    <ul>
      <li>31 July 2021</li>
    </ul>
  </li>
  <li>In order to ensure that all reported thrombotic events with thrombocytopenia and/or bleeding events are investigated by performing an in-depth exploration of platelet function in the interventional study in immunocompromised subjects, the MAH should submit the clinical study report, in accordance with a revised and agreed study protocol.
    <ul>
      <li>30 November 2023</li>
    </ul>
  </li>
  <li>In order to further characterise the thrombosis and thrombocytopenia syndrome associated to the vaccine and elucidate its mechanism, the MAH should conduct suitable clinical studies.
    <ul>
      <li>30 June 2024 with annual updates</li>
    </ul>
  </li>
  <li>Submission of a plan in RMP and timelines
    <ul>
      <li>31 August 2021</li>
    </ul>
  </li>
  <li>Submission of protocols
    <ul>
      <li>30 September 2021</li>
    </ul>
  </li>
  <li>In order to evaluate antibody persistence, the Applicant should submit 6-month immunogenicity data of the COV trials.
    <ul>
      <li>Published data: 31 July 2021</li>
      <li>Follow-up with validated data: 31 January 2022</li>
    </ul>
  </li>
  <li>In order to investigate potential correlate(s) of protection, the Applicant should provide data on breakthrough cases.
    <ul>
      <li>Published data: 31 July 2021</li>
      <li>Detailed analyses on breakthrough cases and validated data on correlates of protection: 31 January 2022</li>
    </ul>
  </li>
  <li>In order to further evaluate vaccine efficacy against transmission, the Applicant should provide updated data from the COV002 study.
    <ul>
      <li>31 January 2022</li>
    </ul>
  </li>
</ul>
</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg height="17" class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" viewBox="0 0 13 17" focusable="false">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>